Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance

NovoCure Ltd (NVCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance Third quarter net revenues of $193 million an increase of 16% year-over-year, driven by 19% growth in active patients worldwide Strong performance drove increased net revenue guidance for full-year 202

Event · Earnings
Also in this documentGuidance · raise · $736M–$743M

Facts are quoted from the filing text and checked against it.

Original reporting
Published Oct 29, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 11:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$NVCR
Bullish
high confidence
Mentioned
$NVCR
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NVCRBullishHigh
01

Why it matters

The raised guidance reflects robust patient growth and margin expansion, likely supporting a price increase.

02

Market read

First‑report earnings and guidance raise for a mid‑cap biotech, offering fresh trading material.

03

What to watch

Potential regulatory delays for new indications could temper growth.

Relevance 8/10Novelty 8/10Timing: pre‑market today
AlphAI · Earnings readNVCR · Third quarter 2026 · ended September 30, 2026

Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance

✓Strong quarter

Third-quarter net revenues increased 16% year-over-year to $193.4 million, gross margin improved to 77% from 73%, adjusted EBITDA was $15.7 million, and the company raised both full-year net revenue and adjusted EBITDA guidance.

Revenue
$193M
16% y/y
United States net revenue
$112M
Gross margin · GAAP
77%
Full year 2026, as of October 29, 2026 outlook
$736 million - $743 million
GM quarterly gross margin in the mid-to-high 70s percent

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net revenues, three months ended September 30, 2026GAAP$193.4M–16%
Cost of revenues, three months ended September 30, 2026GAAP44,529––
Gross profit, three months ended September 30, 2026GAAP148,870––
Gross margin, three months ended September 30, 2026GAAP77%––
Research, development and clinical studies, three months ended September 30, 2026GAAP58,099–8%
Sales and marketing, three months ended September 30, 2026GAAP53,297–(9%)
General and administrative, three months ended September 30, 2026GAAP43,645–(5%)
Total operating costs and expenses, three months ended September 30, 2026GAAP155,041––
Operating income (loss), three months ended September 30, 2026GAAP(6,171)––
Financial income (expenses), net, three months ended September 30, 2026GAAP(1,709)––
Income (loss) before income tax, three months ended September 30, 2026GAAP(7,880)––
Income tax, three months ended September 30, 2026GAAP2,555––
Net income (loss), three months ended September 30, 2026GAAP−$10.44M–(72) %
Basic and diluted net income (loss) per ordinary share, three months ended September 30, 2026GAAP$(0.09)––
Weighted average number of ordinary shares used in computing basic and diluted net income (loss) per share, three months ended September 30, 2026GAAP116,785,198––
EBITDA, three months ended September 30, 2026non-GAAP$(1,755)–(95) %
Share-based compensation, three months ended September 30, 2026non-GAAP17,483–(40) %
Adjusted EBITDA, three months ended September 30, 2026non-GAAP$15.73M–(618) %
Net revenues, nine months ended September 30, 2026GAAP$551,038––
Cost of revenues, nine months ended September 30, 2026GAAP124,564––
Gross profit, nine months ended September 30, 2026GAAP426,474––
Research, development and clinical studies, nine months ended September 30, 2026GAAP167,883––
Sales and marketing, nine months ended September 30, 2026GAAP173,338––
General and administrative, nine months ended September 30, 2026GAAP169,406––
Total operating costs and expenses, nine months ended September 30, 2026GAAP510,627––
Operating income (loss), nine months ended September 30, 2026GAAP(84,153)––
Financial income (expenses), net, nine months ended September 30, 2026GAAP(5,437)––
Income (loss) before income tax, nine months ended September 30, 2026GAAP(89,590)––
Income tax, nine months ended September 30, 2026GAAP7,641––
Net income (loss), nine months ended September 30, 2026GAAP$(97,231)–(13) %
Basic and diluted net income (loss) per ordinary share, nine months ended September 30, 2026GAAP$(0.84)––
Weighted average number of ordinary shares used in computing basic and diluted net income (loss) per share, nine months ended September 30, 2026GAAP115,685,559––
EBITDA, nine months ended September 30, 2026non-GAAP$(71,306)–(31) %
Share-based compensation, nine months ended September 30, 2026non-GAAP97,504–15 %
Adjusted EBITDA, nine months ended September 30, 2026non-GAAP$26,198–(246) %
Total active patients on TTFields therapy globally, September 30, 2026other5,260–19%
Optune Gio active patients, September 30, 2026other4,729–11%
Optune Lua active patients, September 30, 2026other255–83%
Optune Pax active patients, September 30, 2026other276––
Optune Pax prescriptions received, three months ended September 30, 2026other238––

Segments

SegmentRevenueq/qy/y
United States net revenueThe filing reports $4.4 million in net revenue recognized from one-time benefits in the U.S. and Germany related to increases in claims approval rates.$111.9M––
Germany net revenueThe filing reports $4.4 million in net revenue recognized from one-time benefits in the U.S. and Germany related to increases in claims approval rates.$24.9M––
France net revenueNo separate driver was reported.$18.7M––
Japan net revenueOptune Pax received approval from Japan's Ministry of Health, Labour and Welfare for locally advanced pancreatic cancer in October 2026.$14.5M––
Other active markets net revenueNo separate driver was reported.$18.8M––
Optune Lua recognized revenueThe U.S., Germany and Japan contributed $2.3 million, $1.8 million and $4.1 million, respectively.$8.2M––
Optune Pax recognized revenueSubstantially all revenue was from sales in the U.S.$3.7M––
Greater China revenue from Zai Lab partnershipRevenue was from Novocure's partnership with Zai Lab.$4.5M––

Full year 2026, as of October 29, 2026 outlook

  • Revenue$736 million - $743 million
  • Gross marginquarterly gross margin in the mid-to-high 70s percent
  • NoteAdjusted EBITDA: $24 million - $34 million
  • NoteFull-year mid-to-high single digit net revenue growth from Optune Gio
  • NoteNet revenue contribution from Optune Lua and Optune Pax, collectively, between $30 million and $34 million
  • NoteForeign exchange rates as of September 30, 2026

What drove it

  • Total net revenues increased 16% compared with the same period in 2025, primarily driven by 19% global active patient growth.
  • Gross-margin improvement was driven by higher net revenue attributable to higher active patient volumes, lower cost of revenues per active patient, improved array utilization and manufacturing efficiencies.
  • Research, development and clinical study expense increased primarily because of higher clinical trial expenses, mostly attributable to KEYNOTE D58.
  • Sales and marketing expense decreased primarily because of lower share-based compensation expense and lower marketing expense.
  • General and administrative expense decreased primarily because of lower share-based compensation expense.
  • Optune Pax received approval from Japan's Ministry of Health, Labour and Welfare for unresectable locally advanced pancreatic cancer in October 2026.

Concerns

  • Net loss for the quarter was $10.4 million, and operating loss was $(6,171).
  • Operating loss for the nine months ended September 30, 2026 was (84,153), and net loss was $(97,231).
  • Financial income (expenses), net was (1,709) for the quarter compared with 5,999 in the prior-year period.
  • $4.4 million in quarterly net revenue was recognized from one-time benefits in the U.S. and Germany related to increases in claims approval rates.
  • The guidance assumes foreign exchange rates as of September 30, 2026.

What to watch

  • Decision by the U.S. FDA on the premarket approval application for TTFields therapy for brain metastases from non-small cell lung cancer in Q4 2026.
  • Completion of enrollment in the Phase 3 KEYNOTE D58 clinical trial in newly diagnosed glioblastoma in Q4 2026.
  • Net revenue contribution from Optune Lua and Optune Pax, collectively, between $30 million and $34 million for full-year 2026.
  • Quarterly gross margin in the mid-to-high 70s percent assumed in guidance.
  • Optune Gio full-year mid-to-high single digit net revenue growth assumed in guidance.

Balance sheet and cash flow

  • Cash and cash equivalents: $96,734 as of September 30, 2026; $93,548 as of December 31, 2025.
  • Short-term investments: 366,745 as of September 30, 2026; 354,126 as of December 31, 2025.
  • Restricted cash: 10,106 as of September 30, 2026; 9,842 as of December 31, 2025.
  • Cash, cash equivalents and short-term investments were $463.5 million as of September 30, 2026.
  • Trade receivables, net: 108,260 as of September 30, 2026; 89,435 as of December 31, 2025.
  • Inventories: 40,605 as of September 30, 2026; 41,111 as of December 31, 2025.
  • Total current assets: 673,519 as of September 30, 2026; 646,731 as of December 31, 2025.
  • TOTAL ASSETS: $828,708 as of September 30, 2026; $804,326 as of December 31, 2025.
  • Current maturity of senior secured credit facility: $25,000 as of September 30, 2026; $— as of December 31, 2025.
  • Senior secured credit facility, net: 171,337 as of September 30, 2026; 195,047 as of December 31, 2025.
  • TOTAL LIABILITIES: 478,095 as of September 30, 2026; 463,860 as of December 31, 2025.
  • TOTAL SHAREHOLDERS' EQUITY: 350,613 as of September 30, 2026; 340,466 as of December 31, 2025.
  • TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY: $828,708 as of September 30, 2026; $804,326 as of December 31, 2025.

Analysis

Novocure reported $193.4 million of third-quarter net revenues, up 16% compared with the same period in 2025. The company attributed the increase primarily to 19% global active patient growth. Total active patients on TTFields therapy were 5,260 at September 30, 2026, compared with 4,416 at September 30, 2025. Optune Gio active patients were 4,729, up 11%, while Optune Lua active patients were 255, up 83%. Optune Pax had 276 active patients and received 238 prescriptions during the quarter.

Revenue breadth included $111.9 million from the U.S., $24.9 million from Germany, $18.7 million from France, $14.5 million from Japan, $18.8 million from other active markets, and $4.5 million from the Greater China partnership with Zai Lab. Optune Lua and Optune Pax together generated $11.9 million of quarterly net revenue, including $8.2 million from Optune Lua and $3.7 million from Optune Pax. The revenue result included $4.4 million of one-time benefits in the U.S. and Germany related to increases in claims approval rates.

Gross margin improved to 77% from 73% in the prior-year quarter. Novocure cited higher active patient volumes, lower cost of revenues per active patient, improved array utilization and manufacturing efficiencies. Research, development and clinical study expense increased 8% to $58.1 million, mostly attributable to KEYNOTE D58 clinical trial expense. Sales and marketing declined 9% to $53.3 million and general and administrative declined 5% to $43.6 million, with lower share-based compensation cited for both lines.

The company recorded a quarterly net loss of $10.4 million and operating loss of $(6,171), but adjusted EBITDA was $15.7 million versus $(3.0) million in the prior-year period. For the nine months ended September 30, 2026, net revenues were $551,038, adjusted EBITDA was $26,198, operating loss was (84,153), and net loss was $(97,231). Cash, cash equivalents and short-term investments were $463.5 million at September 30, 2026, while the senior secured credit facility had a $25,000 current maturity and a 171,337 long-term balance, net.

Management raised full-year 2026 net revenue guidance to $736 million - $743 million from $710 million - $725 million and raised adjusted EBITDA guidance to $24 million - $34 million from $0 million - $15 million. The updated outlook assumes full-year mid-to-high single digit Optune Gio net revenue growth, Optune Lua and Optune Pax combined net revenue of $30 million - $34 million, quarterly gross margin in the mid-to-high 70s percent, and foreign exchange rates as of September 30, 2026. Near-term operational milestones are the FDA decision on brain-metastases use in Q4 2026 and completion of KEYNOTE D58 enrollment in Q4 2026.

Management, verbatim

Novocure’s strong third quarter performance was driven by continued growth in our Optune Gio business and our growing portfolio of products launching in new markets, resulting in a record number of active patients on our therapies.

Frank Leonard, CEO, Novocure

We achieved record-high quarterly net revenue and are well-positioned to achieve the commercial, clinical and financial goals we set out in January. Based on the results from this quarter, we have raised our financial guidance for 2026 and will continue to build on the strong progress we have made on our path to profitability.

Frank Leonard, CEO, Novocure

Not in the filing

stated, not guessed
  • Operating cash flow was not reported.
  • Free cash flow was not reported.
  • Capital returns, including share repurchases and dividends, were not reported.
  • Quarterly prior-quarter financial comparisons were not reported.
  • A tax-rate guidance figure was not reported.
  • Operating-expense guidance was not reported.
  • A separate previous-release outlook section was not provided, so no actual-versus-prior-guidance comparison is included.
  • Prior-year Optune Pax active patients were not reported as a numeric value.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Novocure disclosed Q3 2026 results and updated its 2026 guidance in an SEC Form 8‑K filing.

Company-level read

Ticker impact

$NVCRBullishHigh confidence
Context

Novocure raised its full‑year 2026 revenue guidance to $736‑$743 million and adjusted EBITDA guidance to $24‑$34 million.

Expected impact

potential upward pressure as the market prices in higher revenue outlook

Evidence & confidence

The company reported 16% revenue growth YoY, record active patients and improved gross margin, prompting an upward revision of guidance that should support a price rally.

Market effects

Strengthens outlook for oncology and medical‑device sector.

Positive for U.S. and European biotech markets.

Adds confidence to global cancer‑therapy innovation narrative.

Counterpoint

If the guidance raise is already priced in, the stock may face limited upside.

Key entities

  • Novocure Ltd

    Global oncology firm developing Tumor Treating Fields therapy.

Every NVCR earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$NVCRLowAI 8/10

JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields for Pancreatic Cancer

Novocure (NVCR) announced that JAMA Network Open published results from the PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for pancreatic cancer. The trial met its primary endpoint, showing improved overall survival. Secondary endpoints also demonstrated significant benefits in pain management and quality of life. TTFields therapy was well-tolerated with no new safety signals. Novocure aims to inform clinicians and patients with these findings.

$NVCRMedAI 8/10

FDA Rejects NovoCure’s Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.

NovoCure's (NVCR) shares fell 6% after the FDA rejected its Optune Mya device for lung cancer brain metastases, citing uncertainty about clinical benefits. The company plans to meet with FDA officials to discuss a potential approval path. NovoCure's other Optune devices, Gio, Lua, and Pax, are approved and generating revenue, but the company remains unprofitable. The FDA's decision adds to investor concerns about competition from Revolution Medicines' Rasonque pill.

$NVCRHighAI 9/10

Novocure’s device for treating brain metastases rejected by FDA

The FDA rejected Novocure's PMA for Optune Mya, a device for treating brain metastases, citing uncertainty about clinical benefits. The FDA did not raise safety concerns. Novocure plans to discuss feedback with the FDA to explore approval options, but there is no guarantee of future approval. The company has FDA approvals for other TTFields therapies, including Optune Gio, Lua, and Pax.